SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca disclosed preliminary Phase 1 data for its RAS-targeting drug…

Erasca, Inc. · 8-K filed Apr 27, 2026 at 08:31 ET

At the news

MIXEDIMPACT 7/10

8-K filed Apr 27, 2026 at 08:31 ET

Erasca disclosed preliminary Phase 1 data for its RAS-targeting drug ERAS-0015 while simultaneously revealing a patent and trade secret infringement claim from Revolution Medicines. The litigation threat over a key asset creates significant near-term uncertainty despite the positive clinical update.

  • Erasca announced a webcast to discuss preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue for RAS-mutant solid tumors.
  • Revolution Medicines (RevMed) alleged that ERAS-0015 infringes its U.S. Patent No. 12,409,225 under the doctrine of equivalents.
  • RevMed also claimed Erasca is liable for misappropriation of trade secrets related to ERAS-0015 and accused the company of making deceptive comparative statements.
  • RevMed demanded Erasca cease all development and commercialization activities for ERAS-0015 in the U.S. outside the Hatch-Waxman safe harbor.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access